Korro Bio

Korro Bio

Develops RNA-based therapies for diseases

About Korro Bio

Simplify's Rating
Why Korro Bio is rated
A
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A+ on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

IPO

Total Funding

$383.7M

Headquarters

Cambridge, Massachusetts

Founded

2019

Overview

Korro Bio develops RNA-based therapies aimed at treating serious diseases that currently lack effective treatments. The company uses RNA editing to make precise modifications at the RNA level, which allows for accurate changes to protein function. This method is seen as more precise and potentially safer than traditional gene editing techniques. Korro Bio focuses on research and development to create new therapies, which it can market independently or through partnerships with larger pharmaceutical companies. The company serves healthcare providers, hospitals, and patients, and collaborates with academic institutions to enhance its research. Korro Bio's goal is to make significant scientific advancements in medicine accessible to patients in need.

💵
Funded Recently
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnership with Novo Nordisk enhances cardiometabolic disease treatment development.
  • Recent $70M funding boosts clinical trials and platform development.
  • Growing interest in RNA editing technologies supports market expansion.

What critics are saying

  • Increased competition from companies like Beam Therapeutics and Editas Medicine.
  • Potential regulatory hurdles could delay product approvals.
  • Market volatility may affect Korro Bio's stock performance.

What makes Korro Bio unique

  • Korro Bio uses RNA editing for precise protein function modifications.
  • Their platform targets diseases with limited or no current treatment options.
  • Korro Bio's RNA editing is more accurate than traditional gene editing methods.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$383.7M

Above

Industry Average

Funded Over

3 Rounds

Notable Investors:
Private Placement VC funding comparison data is currently unavailable. We're working to provide this information soon!
Private Placement VC Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Stock Titan
Jan 7th, 2025
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Investing.com
Oct 16th, 2024
KRRO stock soars to 52-week high, touches $98 amid robust gains

In other recent news, Korro Bio has announced a strategic partnership with Novo Nordisk (NYSE:NVO), a global healthcare company, to develop genetic medicines for cardiometabolic diseases.

BioSpace
Sep 16th, 2024
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

Korro Bio announces collaboration with Novo Nordisk to develop two therapeutic candidates.

BioPharm International
Sep 16th, 2024
Novo Nordisk and Korro Bio Collaborate on Cardiometabolic Treatments

Korro Bio, a Massachusetts-based biopharmaceutical company that develops genetic medicines based on RNA editing, announced on Sept. 16, 2024 that it is collaborating with Novo Nordisk to develop targets to treat cardiometabolic diseases, such as obesity, diabetes, and cardiovascular diseases.

TipRanks
Apr 18th, 2024
Korro Bio Raises $70M for Clinical Trials and Growth

Korro bio raises $70M for clinical trials and growth.

Recently Posted Jobs

Sign up to get curated job recommendations

Korro Bio is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Korro Bio's jobs every 8 hours, so check again soon! Browse all jobs →